血管紧张素转换酶抑制剂暴露后银屑病:法国药物警戒数据与文献综述
67%的报告发病时间小于1年,73%在停用ACEI后结局良好,文献中也有21例报告。结论认为ACEI与银屑病存在统计学显著关联,属于类效应,建议所有ACEI的SmPC中提及银屑病风险。
要点
- ACEI暴露与银屑病存在统计学显著关联(ROR 2.40,95%CI 1.96-2.95)。
- 多数报告发病时间小于1年,停药后73%结局良好。
- 风险为类效应,几乎所有ACEI均涉及,建议SmPC中提及。
核心结论
- ACEI暴露与银屑病存在统计学显著关联,构成潜在安全性信号。
- 银屑病风险为ACEI类效应,发病时间通常小于1年,停药后结局良好。
- 建议所有ACEI的SmPC中提及银屑病风险,并告知医疗专业人员。
研究设计与样本
- 采用病例/非病例方法评估银屑病与ACEI暴露的关联。
- 同时回顾了文献中关于ACEI相关银屑病的报告。
主要发现
- 报告比值比为2.40(95%CI 1.96-2.95)。
- 67%的报告发病时间小于1年。
- 73%的报告在停用ACEI后结局良好。
- 文献中检索到21份ACEI相关银屑病报告,发病时间范围为1周至4个月。
关键数值与推荐
- 报告比值比为2.40(95%CI 1.96-2.95)。
- 67%的报告发病时间小于1年。
- 73%的报告在停用ACEI后结局良好。
- 文献报告中发病时间范围为1周至4个月,超过半数停药后结局良好。
临床怎么用
- 临床应警惕ACEI暴露后银屑病的发生,尤其用药后1年内。
- 疑似ACEI相关银屑病时,停药后多数患者结局良好。
- 建议医疗专业人员了解ACEI类药物的银屑病风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Angiotensin-converting enzyme inhibitors (ACEIs) can induce or aggravate psoriasis. This risk is not specified in the Summary of Product Characteristics (SmPC) of some drugs of this class, such as captopril or enalapril. We aimed to investigate the association between psoriasis and ACEI exposure. METHODS: We analyzed spontaneous reports recorded in the French national Pharmacovigilance Database (FPVD) from 1985 to 31 December 2018. The association between psoriasis and ACEI exposure was assessed using the case/non-case method. We also reviewed literature reports. RESULTS: One hundred reports of psoriasis after ACEI exposure were registered in the FPVD. The reporting odds ratio (ROR) was 2.40 (95% CI 1.96-2.95). Time to onset was < 1 year in 67% of reports. Outcome was favorable in 73% of reports after ACEI discontinuation. Almost all ACEIs were concerned. In the literature, we found 21 published reports of psoriasis with ACEIs. Time to onset ranged from 1 week to 4 months. Outcome was also favorable after ACEI discontinuation in over half of the literature reports. CONCLUSIONS: We found a statistically significant association between psoriasis and ACEI, which constitutes a potential safety signal. The risk of psoriasis is a class effect, time to onset is less than 1 year, and outcome is favorable after ACEI discontinuation. Psoriasis should be mentioned in the SmPCs of all ACEIs, and healthcare professionals should be informed about this risk.
引用
- Azzouz B, Morel A, Kanagaratnam L, et al. Psoriasis After Exposure to Angiotensin-Converting Enzyme Inhibitors: French Pharmacovigilance Data and Review of the Literature. Drug Saf. 2019. PMID: 31598933. doi:10.1007/s40264-019-00865-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。